EICHORPublic-registry site landscape for NCT04023331, “67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma”, a Neuroblastoma study sponsored by Clarity Pharmaceuticals Ltd. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04023331 (registry record) |
| Study title | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma |
| Official title | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial |
| Sponsor | Clarity Pharmaceuticals Ltd |
| Condition(s) | Neuroblastoma; Relapsed Neuroblastoma; Refractory Neuroblastoma |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 8 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04023331.
Eichor generates a preliminary site-risk snapshot for NCT04023331 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
